Taxotere Lawsuit

The Rise of Taxotere Litigation

 

Taxotere (docetaxel) is a chemotherapy drug manufactured by Sanofi-Aventis. The FDA approved it in 1996 for the treatment of various cancers, including breast, lung, prostate, and gastric cancers. While Taxotere has been effective in cancer treatment, patients and healthcare professionals began reporting serious, long-term side effects that the manufacturer did not adequately disclose. These reports have led to a growing number of Taxotere lawsuits as individuals seek compensation for permanent hair loss and other serious complications linked to the drug.

The most well-known side effect is permanent hair loss (alopecia), which was not listed as a risk in early versions of the drug’s labeling in the United States. Patients prescribed Taxotere for chemotherapy have reported permanent, irreversible hair loss years after treatment, leading to significant emotional distress and reduced quality of life.

In addition to hair loss, recent lawsuits have focused on Taxotere’s link to serious eye injuries, including excessive tearing (epiphora), canalicular stenosis, and other vision-related complications. These conditions can be painful, require surgical intervention, and lead to permanent damage.

Understanding the Taxotere MDLs

 

Due to the volume of claims, two separate Multidistrict Litigations (MDLs) have been established for Taxotere-related injuries.

Taxotere Hair Loss Lawsuits – MDL No. 2740

 

This MDL consolidates claims from individuals who suffered permanent alopecia after receiving Taxotere during chemotherapy treatment. Plaintiffs allege that Sanofi-Aventis failed to warn about the risk of permanent hair loss adequately.

Taxotere Eye Injury Lawsuits – MDL No. 3023

 

  • Case Name: In Re: Taxotere (Docetaxel) Eye Injury Products Liability Litigation
  • MDL Number: 3023
  • Jurisdiction: U.S. District Court for the Eastern District of Louisiana
  • Presiding Judge: Honorable Jane Triche Milazzo
    This newer MDL includes lawsuits filed by patients who developed epiphora (excessive tearing), canalicular stenosis, and other serious eye injuries due to Taxotere. These eye complications often require invasive surgery and can result in permanent damage.

Both MDLs remain active, with ongoing litigation, discovery, and bellwether trials. As of 2025, hundreds of cases are still pending.

Serious Side Effects Linked to Taxotere

 

Permanent Hair Loss (Alopecia)

 

Many cancer survivors expected hair regrowth after completing chemotherapy. However, patients treated with Taxotere have reported permanent, irreversible hair loss on the scalp, eyebrows, eyelashes, and other body areas. Sanofi did not include this risk on the U.S. label until 2015—years after reports surfaced and warnings were issued in Europe and Canada.

Excessive Tearing and Eye Damage (Epiphora and Canalicular Stenosis)

 

Taxotere has been linked to tear duct damage, which can cause chronic watery eyes, infections, inflammation, and canalicular stenosis, a condition in which the tear ducts become narrowed or blocked. In severe cases, patients may require dacryocystorhinostomy (DCR) surgery to relieve the symptoms, and even then, vision issues may persist.

 

Why This Matters to Patients

 

Patients and survivors are entitled to honest information about the medications they receive. However, Taxotere users were not adequately warned about the risks of permanent alopecia or eye injuries, thereby depriving them of the ability to make informed decisions about their healthcare.

Moreover, permanent hair loss and debilitating eye injuries affect not only physical health but also emotional well-being and quality of life. Consequently, lawsuits allege that Sanofi-Aventis prioritized profit over patient safety by downplaying or withholding this crucial information.

 

Why Choose Gallon, Takacs & Boissoneault?

 

At Gallon, Takacs & Boissoneault, we understand the profound impact that permanent hair loss and eye injuries can have on cancer survivors. Our legal team has over 70 years of experience representing individuals harmed by dangerous drugs and medical devices.

We are actively reviewing cases of individuals who have suffered:

  • Permanent Hair Loss (Alopecia) after Taxotere chemotherapy
  • Eye Injuries, including epiphora and canalicular stenosis, linked to Taxotere

Our firm is committed to holding pharmaceutical companies accountable and fighting for justice on behalf of injured patients.

 

Contact Gallon, Takacs & Boissoneault for a Free Case Evaluation

 

If you or a loved one has suffered permanent hair loss or eye injuries after using Taxotere, you may be eligible for compensation through ongoing MDL litigation.